Back

The first peer-reviewed results of #lecanemab for #Alzheimers disease are now out:

https://www.nejm.org/doi/full/10.1056/NEJMoa2212948

Bottom line:
- very modest cognitive benefit: 0.45 difference between lecanemab & placebo on an 18-point scale (CDR-SB) over 18 months
- fair amount of side effects, including ARIA-H, ARIA-E & infusion reactions (though appear to be fewer than with #aducanumab).